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doi:10.1016/j.ejvs.2009.08.007Abstract Introduction: This study reports the technical and mid-term clinical results of the
second-generation Anaconda AAA Stent Graft System endovascular device for treatment of
abdominal aortic aneurysm (AAA). The design of the Anaconda AAA Stent Graft System is
characterised by a three-piece system consisting of two proximal independent saddle-shaped
nitinol self-expandable rings with hooks fixation, zero body support and vacuum-cleaner tube
leg design.
Methods: From July 2002 to April 2005, a total of 61 patients with AAA were enrolled in a multi-
centre, prospective, non-randomised controlled design study. All patients received a second-
generation Anaconda AAA Stent Graft System. They entered a standard follow-up protocol at
discharge for 3, 6, 12 and 24 months. Follow-up data included survival; rupture-free survival;
incidence of aneurysm rupture, death from aneurysm rupture, aneurysm-related death;
freedom from aneurysm expansion; freedom from Types I and III endoleaks; endograft patency
and technical and clinical success rates.
Results: Successful access to the arterial system was achieved in all patients. The primary
technical success was 59 out of 61 and the primary assisted technical success was 60 out of
61. All endovascular grafts were patent without significant twists, kinks or obstructions. Migra-
tion was not observed in any of the grafts. During the first 30-day period, two serious adverse
events (3%), both not related to the procedure, were observed. Nine patients (15%) needed
a secondary intervention; two of these interventions were related to stent graft (3%). The
mean aneurysm sac diameter decreased significantly from 57 mm pre-operative to 45 mm after
24 months, without aneurysm growth. There was one Type I endoleak at initial implantation,3 4872510; fax: þ31 53 4872526.
enhuis-mst.nl (R.H. Geelkerken).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Clinical Evaluation Anaconda 733which was corrected using a proximal extension cuff. In total, three Type II endoleaks were
still present after 24 months without any signs of aneurysm growth.
Conclusion: The design features of the second-generation Anaconda AAA Stent Graft System
are effective in the treatment of AAAs on mid-term evaluation.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Table 1 Anaconda 004 AAA stent graft study.
Inclusion criteria
- Patients aged 18 yearse85 years
- Patient willing and available to comply with follow-up
requirements
- Patient can comply with instructions and give informed
consent
- Life Expectancy >2 years
- Patient is a candidate for open surgical repair
- AAA >50 mm in diameter
- Infrarenal proximal neck diameter 18e31.5 mm
- Infrarenal proximal neck length >15 mm
- Distal Iliac fixation site diameter <16 mm and >30 mm in
length
- Access vessels >7.5 mm in diameter
Exclusion criteria
- Ruptured AAA
- Symptomatic AAA
- Juxta or suprarenal extension of aneurysm
- Presence of serious concomitant medical disease
or infection
- Known allergy to contrast medium, nitinol or polyester
- Inability to preserve at least one hypogastric artery
- Connective tissue disease
- ASA Grade IV or V
- Need for surgical reconstruction of other visceral arteries
- Infrarenal aortic angulation >45
- Presence of >50% continuous calcification of proximal neck
- Presence of >50% thrombus in proximal neck
- Presence of conical infrarenal neck
- Other unsuitable anatomyWith the primary objective to exclude the abdominal aorta
aneurysm (AAA) sac from the arterial circulation and to
consequently eliminate the risk of aneurysm rupture, several
endovascular graft devices were developed during the past
2 decades. The basic concept of endoluminal AAA exclusion
has not changed during this period but the failure modes
observed during this era inspired companies and clinicians to
reappraise the endograft design configurations.
First-generation homemade devices were custom-made
endografts using off-the-shelf stents combined with various
graft materials used for conventional vascular procedures.1
Clinical experiences were rapidly gained with second-
generation, commercially available endoprostheses in the
1990s, which were used in the USA and Europe depending
upon regulatory approval status.2,3 Various failure modes of
these stent grafts were identified. The two most clinically
significant failures are endoleak (particularly Types I and III)
and migration,4e6 ranging between 10% and 30% 1 year after
graft placement depending on endograft type.
The first-generation Anaconda AAA Stent Graft System
was developed without hooks and completely relied on
friction sealing for proximal fixation. The second-genera-
tion Anaconda AAA Stent Graft System has been rede-
signed with the intention of addressing the failure modes
observed in the earlier generations of stent grafts,
including the first-generation Anaconda.6e9 The two major
modifications were the introduction of proximal hooks
connected to the proximal two-ring stents and the intro-
duction of the zero body support of the graft, both with the
intention to decrease the chance of migration. The name
Anaconda was chosen because of the similarity between
the shape of the proximal ring stent and a snakes’ mouth.
The second-generation Anaconda AAA Stent Graft System
was CE marked in April 2005.
This study reports on the technical and the mid-term
clinical results of the second-generation Anaconda AAA
Stent Graft System for the treatment of AAA.
Materials and Methods
Study design
From July 2002 to April 2005, a total of 61 patients with AAA
were enrolled in a multicentre, prospective, non-rando-
mised controlled study (Anaconda 004 study). Each patient
underwent a detailed pre-operative screening to ensure
that the general medical condition was satisfactory
for conversion from endovascular aneurysm repair (EVAR)
to conventional repair, if necessary. The information
collected consisted of a general health analysis including
the Society of Vascular SurgeryeInternational Society
of Cardiovascular Surgeons (SVSeISCVS)10 risk scores for
diabetes, smoking, hypertension, hyperlipidaemia, cardiac
status, carotid disease, renal status, pulmonary status andAmerican Society of Anesthesiologists (ASA) classification.
pre-operative AAA assessment included detailed spiral
computed tomography (CT) scanning and standard contrast
arteriography as detailed in the Core Laboratory Protocol.
The selected medical and anatomical inclusion and exclu-
sion criteria are listed in Table 1.
Study hypothesis and definitions
The primary objectives of this study were to examine the
technical and clinical success of the Anaconda AAA Stent
Graft System for the treatment of AAA. The following
definitions, in line with the suggestions of Chaikof et al.,
were used.11
Technical success was defined as successful access to the
arterial system using a remote site, successful deployment
of the stent graft with secure proximal and distal sealing
and fixation of the attachment devices, demonstrating safe
and effective exclusion of the AAA without Type I or III
endoleak and patent endoluminal graft without significant
Figure 1 The Anaconda AAA Stent Graft System (Vascutek, Terumo, Inchinnan, Scotland) is a three-pieces endovascular device
made of multiwire twisted nitinol stents combined with woven graft material. The proximal ring stent is anchored in an infrarenal
position by four pairs of nitinol hooks that prevent device migration. The cannulation of the contralateral gate of the body is
facilitated by a unique magnet system.
734 S.G.J. Ro¨del et al.twists, kinks or obstruction by intra-operative angiography
measurements periprocedural and in the first 24-h period.
In case of unplanned endovascular or surgical procedures, it
was defined as assisted primary or secondary technical
success.
Clinical success was defined as successful deployment of
the endovascular device at the intended location without
death as a result of aneurysm-related treatment, Types I
and III endoleak, graft infection or thrombosis, aneurysm
expansion (diameter 5 mm, or volume 5%), aneurysm
rupture or conversion to open repair. In cases with Type II
endoleak, clinical success was only claimed in the absence
of aneurysm expansion. Primary clinical success is clinical
success without the need for an additional or secondary
surgical or endovascular procedure. Secondary clinical
success is clinical success obtained with the use of an
additional or secondary surgical procedure.
Clinical failure included a failure to deploy the endo-
vascular device at the intended location, the presence of
a Type I or III endoleak, graft thrombosis or infection, graftdilatation of 20% or more by diameter, graft migration,
failure of device integrity, aneurysm expansion or rupture,
conversion to open repair or death.
A serious adverse event was defined as any clinical
event, which resulted in death, or was life-threatening,
produced permanent or significant disability/incapacity,
resulted in-patient hospitalisation or prolongation of
existing in-patient hospitalisation, is a cancer or required
medical or surgical intervention to prevent permanent
impairment of function or permanent damage to a body
structure.
Clinical success is reported as short-term clinical success
(30 days) and mid-term clinical success (2-years’ follow-up).
Device description
The Anaconda AAA Stent Graft System (Vascutek, Terumo,
Inchinnan, Scotland, UK) is a three-piece endovascular
device made of multiple element nitinol stents combined
with woven polyester graft material. The top of the graft
Figure 2 Repositionable proximal neck.
Clinical Evaluation Anaconda 735consists of a dual-ring stent design, which provides hae-
mostatic sealing against the vessel wall. The proximal ring
stent is anchored in an infrarenal position by four pairs of
nitinol hooks, which prevent device migration (Fig. 1). The
body is unstented, resulting in zero column strength, which
is comparable to conventional bifurcated prosthesis design.
The iliac legs are fully supported with independent nitinol
ring stents, which provide flexibility and prevent kinking in
tortuous anatomy. The cannulation of the contralateral
gate of the body is facilitated with a magnet system
(Fig. 1). The delivery device of the body is flexible, kink
resistant and allows multiple rotational, proximal and distal
repositioning (Fig. 2). The delivery system of the main body
has an outer diameter of 20.4 or 22.5 French (6.8e7.5 mm),
depending of the stent graft neck diameter used. The
delivery system for the iliac legs has an outer diameter of
18.3 French (6.1 mm).
AAA sizing and stent-graft selection were in line with the
recommendations of the Anaconda AAA Stent Graft
System and sizing reference chart. The oversizing at the
level of the infrarenal neck was between 7.3% and 21.8%,
and at the level of the common iliac artery between 5% and
28.5%, respectively.
Operative procedure
The operation was performed under local, epidural or
general anaesthesia in the operating room with a radiolu-
cent table under fluoroscopic guidance. The procedure
required surgical exposure of the femoral arteries or
common iliac arteries and was performed by surgical
cut down and formation of an arteriotomy. During the
procedure, intravenous heparin 5000 IU or 100 IU heparin
per kg body weight was required in accordance with stan-
dard endovascular procedures. The surgical technique was
carried out in accordance with the Vascutek Limited
Instructions for Use (see www.vascutek.com). All the
necessary operative details, overall outcome of the
procedure as well as any adverse events during the opera-
tion were recorded using the case report form.
Follow-up protocol
All patients were enrolled in a standard follow-up protocol
at discharge and at 3, 6, 12 and 24 months. Each patient
underwent a postoperative contrast-enhanced computed
tomography (CT) scan and plain abdominal radiograph. All
radiological data were independently reviewed by a core
lab (Cleveland Clinic, Cleveland, OH, USA).
Recorded follow-up data included survival, rupture-free
survival, incidence of aneurysm rupture, death from aneu-
rysm rupture, aneurysm-related death, freedom from
aneurysmexpansion, freedom fromTypes I and III endoleaks,
endograft patency and technical and clinical success rates.
Statistical analysis
Results are reported as mean standard deviation (SD;
range) or with a 95% confidence interval where appropriate.
Student’s t-test was used to compare continuous variables.
Significance was assumed at a P value of less than 0.05. TheKaplaneMeier curves and log-rank tests were used to plot
survival over time. The statistical analyses of this study
were carried out by an independent statistician.Results
Demographics
Relevant patient characteristics are presented in Table 2.
The patients’ age ranged between 51 and 87 years with
a mean of 71 years. The average aneurysm sac diameter
was 57 mm (range: 50e83 mm).
Technical success
The technical results are summarised in Table 3. In all
patients, successful access to the arterial system was ach-
ieved. In all cases the body of the Anaconda AAA Stent
Graft System could be precisely positioned and, if neces-
sary, repositioned using the delivery device. One implan-
tation could not be completed due to the accidental loss of
the guide-wire of the main body during operation. The local
physician decided to convert to conventional open repair.
Access to the contralateral gate was quick and easy. Intra-
operatively, there was one Type I endoleak, which was
treated successfully with a proximal extension cuff. There
were no Type III endoleaks. All endoluminal grafts were
patent without significant twist, kinks or obstruction.
Short-term clinical success
The short-term clinical outcome is summarised in Table 3.
During the first 30-day period, there were two serious
adverse events resulting in death: one patient died due to
Table 3 Anaconda 004 AAA stent graft study: technical
success and clinical success.
30 days 2 years
Primary technical
success
96.7% (59/61)a,b
Primary assisted
and secondary
technical success
98% (60/61)a
Primary clinical
success
93% (57/61)c,d,e,f 72.1% (44/61)
Secondary clinical
success
95% (58/61)c 88.5% (54/61)
Serious adverse
events
3.2% (2/61)e,f 11.4% (7/61)
Clinical failure 4.9% (3/61)d,e,f 11.4% (7/61)
All cause mortality 9.8% (6/61)
Aneurysm-related
mortality
0% (0/61)
Freedom from
re-intervention
85.2% (52/61)
Freedom from
migration
100% (60/60)
a One conversion due to loss of the guide-wire.
b One Type I endoleak. Proximal extension cuff resolved
endoleak.
c Type I endoleak during operation, proximal extension cuff
needed.
d One conversion due to loss of guide-wire. Clinical failure.
e Death due to cardiac arrest, not device related. Clinical
failure.
f Severe lung bleeding. Not device related. Clinical failure.
Table 2 Anaconda 004 AAA stent graft study; patient
characteristics.
Demographic Present study,
number of patients
(range or %)
Age (years) Mean (Range) 71.2 (51e87)
Gender Male 60 (98.4)
Female 1 (1.6)
ASA grade I 3 (4.9)
II 38 (62.3)
III 19 (31.1)
Unknown 1 (1.6)
Diabetes Only diet controlled 9 (14.8)
Hypertension None 16 (26.2)
Drug controlled 43 (70.5)
uncontrolled 2 (3.3)
Hyperlipidaemia Normal 26 (42.6)
Mild 20 (32.8)
Diet and or drugs 14 (23)
Not recorded 1 (1.6)
Cardiac status Normal 30 (49.2)
Asymptomatic - MI 18 (29.5)
angina etc. 13 (21.3)
Renal disease Normal 57 (93.4)
Increased 4 (6.6)
Pulmonary disease Normal 48 (78.7)
Mild 9 (14.8)
Moderate/severe 4(6.5)
736 S.G.J. Ro¨del et al.a cardiac arrest 8 days after EVAR and another died as
a result of a severe lung bleeding12 h after an uncompli-
cated EVAR. The cause of death in the second patient was
a ruptured bronchial artery in a necrotic lung segment due
to radiotherapy for bronchial carcinoma 2 years earlier,
which could not be foreseen. At autopsy, it was confirmed
that the AAA exclusion with the Anaconda Stent Graft was
uncomplicated in both cases. Other early serious adverse
events were not experienced.
Mid-term clinical results
The mid-term clinical outcome is summarised in Tables 3
and 4 and Fig. 3.
The 2-year loss to follow-up was zero. There were seven
serious events including four additional deaths after 30
days (heart failure (2), carcinoma and CVA) and one patient
with occlusion of an iliac device leg, treated successfully
with a PTA procedure. There were no aneurysm-related
deaths. There were no device fixation failures at the
proximal neck, specifically no wire or hook fractures or
migrations at 2 years. Nine patients needed a secondary
intervention; two of these interventions were related to
graft.
The mean aneurysm sac diameter decreased signifi-
cantly from 57 mm (7 mm) pre-operative to 45 mm(11 mm) after 24 months evaluation (p 0.0001). At 24
months no patient had an increase of the aneurysm sac
diameter, eight patients remained stable and 39 patients
had a decrease of the aneurysm sac of 5 mm or more. Eight
patients were not evaluated at 24 months, but all these
patients showed no increase at 18 months’ follow-up.
Endoleak
Neither Type III nor Type IV endoleaks were observed during
the 2-years’ follow-up.
One Type I endoleak occurred during operation, which
was corrected intra-operatively using a proximal extension
cuff and Palmaz balloon-expandable stent. Retrospectively,
less than 6% oversizing of the Anaconda stent caused this
problem. Eight Type II endoleaks, seven lumbar artery and
one inferior mesenteric artery were observed intra-opera-
tively. One patient with a Type II endoleak died 8 days
after discharge due to cardiac arrest. In two other patients
with stable aneurysm diameter, coiling of a Type II endoleak
was performed at 3 months. One Type II endoleak dis-
appeared spontaneously after 18 months and another after
24 months. A new Type II endoleak was discovered at 12
months follow-up and disappeared spontaneously at 18
months follow-up. In total, three Type II endoleaks were still
present after 24 months without any signs of aneurysm
growth.
Table 4 Anaconda 004 AAA stent graft study; re-interventions.
Patient Re-intervention Details Follow-up
25 Coiling Patient had persistent Type II
lumbar endoleak. Elective
angiography with attempt to
coil.
3 m
23 Coiling Patient has a new Type II
collateral vessel endoleak.
Collateral vessels coiled.
3 m
1 Iliac Extension to treat
aneurysm.
Patient had distal iliac
aneurysm successfully treated
with an Anaconda iliac
extension.
10 m
47 Iliac Extension to treat
dilatation.
Increased diameter of left CIA. 12 m
5 Fem Fem Right iliac obstruction with
stenosis in external iliac artery.
3 m
33 Thrombendarterectomy & SFA
Proximal Vein Patch Plasty
Occlusion of artery access. 15 m
3 PTA Femoral artery occlusion. High
grade stenosis of common
femoral artery.
12 m
58 PTA Internal iliac occlusion. 12 m
27 Thrombectomy & Stent Right iliac device obstruction 16 m
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The second-generation Anaconda AAA Stent Graft System
was introduced in the clinic 6 years ago. The present report
focusses on the technical and the mid-term clinical success
of this new device.
Including the 61 patients in this present study, until now
technical success has been reported in 173 out of 175
patients (99%) receiving an Anaconda stent graft.12e14
These results are comparable with the Zenith and Excluder
trials recently published.6,15
The only conversion in the present series was due to loss
of guide-wire access while no additional endovascular
equipment, such as long wires for a brachial approach,
a goose neck or a shepherd’s hook catheter, was available
at the local site to resolve the problem. In our opinion, lack
of technical success in this case was not related to any
failure of the Anaconda system.
The present multicentre prospective, core lab-
controlled study determined the mid-term clinical
outcome of AAA patients treated with the Anaconda
AAA Stent Graft System. In line with the in- and exclu-
sion criteria, selecting anatomically and physically
favourable patients, excellent outcomes should be
feasible. The 2-year overall mortality rate of 10%, none
related to aneurysm, was comparable with the DREAM
trial,16 although 30-day mortality in our group was
slightly higher (3.2% vs. 1.1%). In particular, the low
incidence of Types I and III endoleaks, the absence of
migration, the absence of increase of aneurysm diam-
eter and the 100% rupture-free survival were considered
to be excellent and comparable with the Zenith and
Excluder trials.6,15One special feature of the Anaconda AAA Stent Graft
System is the possibility of using the magnetic docking
system for cannulation of the contralateral gate. Although
time to access to the contralateral gate was not part of the
study protocol, the personal experience of the participants
was that the magnetic system significantly reduced the
cannulation time of the contralateral side compared with
standard cannulation techniques. Other single-centre
studies reported a mean contralateral cannulation time of
4 min (range: 3e22 min) with a magnetic coupling success
rate of 94e100%.12e14 After modification with stronger
magnets in the year 2005, a further reduction of the can-
nulation time of the contralateral body was achieved
according to Stehr.13
Another special feature of the Anaconda AAA Stent
Graft System is the possibility of repositioning the two
proximal sealing and fixation stent rings. This feature
allowed accurate infrarenal placement in angulated
necks as well. Repositioning rates reported in the liter-
ature varied between 38% and 10% to achieve more
satisfactory stent-graft positions.12e14 The Anaconda
AAA Stent Graft System is not more difficult in stent
placement than are other systems, and getting the most
optimal result using a repositional system during the
intervention is attractive and forgiving in first-time
suboptimal stent placement. Most stents do not have
this feature and stent replacement could be difficult to
achieve. The saddle-shaped proximal ring design facili-
tates adaptation to local anatomy, also during the first
few days after implantation. If this occurs, the valley of
the proximal stent ring could migrate a few millimetres
upstream. If the Anaconda is placed juxtarenal with the
valleys functioning as scallops around the renal orifices,
Months N=0 3 6 9 12 15 18 21 24 
Patient at risk 60 58 58 57 56 55 55 55 54 
No Deaths 2 0 0 1 1 1 0 0 1 
Cumulative 
survival 
96.7% 96.7% 95% 95% 93.3% 91.7% 91.7% 91.7% 90% 
Cumulative 
mortality 
3.3% 3.3% 5% 5% 6.7% 8.3% 8.3% 8.3% 10% 
months
24,0021,0018,0015,0012,009,006,003,000,00
1,00
0,95
0,90
0,85
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Figure 3 KaplaneMeier survival curve survival.
738 S.G.J. Ro¨del et al.we advise placement of short balloon-expandable stents
in these orifices to prevent renal artery stenoses or
occlusion.
It is noted that although the number of leg occlusions
observed was reasonably low and comparable to other
devices, the majority of occlusions in the current world-
wide Anaconda experience is observed in the combination
of small body diameter (<25 mm) and relatively large
diameter legs. Consequently, the sizing and reference chart
concerning the body leg combination was recently adjusted
to this latest worldwide experience and, on short notice,
the docking zone diameter of the small bodies will be
enlarged.
The secondary intervention rate of 15%, including coil
embolisation of a Type II endoleak in two patients with
stable aneurysm diameter, was comparable with other
prospective studies and represents the known difference
between conventional surgical repair, with a low incidence
of secondary interventions, and EVAR.17 Most vascular
centres do not advise coil embolisation in asymptomatic
patients with a Type II endoleak in case of stable aneurysm
diameter.
We conclude that the design features of the second-
generation Anaconda Stent Graft System allow easy
placement of the stent and are effective in the mid-term in
the treatment of AAAs in patients with straightforward
anatomy. Studies focussing on patients with challengingAAA anatomy and patients with rupture AAA will shed
further light on the additional clinical value of the
Anaconda AAA Stent Graft System design.Conflict of Interest
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